eligibility_summary
Adults 18–70 with newly diagnosed, measurable MM, treatment‑naïve and planned for high‑dose therapy/ASCT, ECOG 0–2, adequate marrow, liver, renal, acceptable labs. FOCBP: 2 negative pregnancy tests and contraception. Exclude prior MM therapy/ASCT (except brief steroids), prior allo/organ transplant, ≥Grade 2 neuropathy, MDS/recent cancers, recent plasmapheresis/RT, FEV1<50%, significant medical/psychiatric or cardiac disease, allergies to study drugs, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in newly diagnosed multiple myeloma using D‑VRd induction and consolidation around high-dose therapy/ASCT, while evaluating blood-based mass spectrometry MRD vs marrow MRD. Interventions and mechanisms: Daratumumab (SC anti‑CD38 IgG1 monoclonal antibody) targets CD38 on malignant plasma cells, inducing ADCC, CDC, ADCP, and apoptosis, Bortezomib (proteasome inhibitor) blocks the 26S proteasome, triggering ER stress/UPR, inhibiting NF‑κB, and causing apoptosis, Lenalidomide (IMiD) binds cereblon, leading to IKZF1/3 degradation, enhancing T/NK cell activity and direct antimyeloma effects, Dexamethasone (glucocorticoid) activates the glucocorticoid receptor, promoting lymphocyte apoptosis and anti-inflammatory effects. Targets/pathways: CD38+ plasma cells, ubiquitin–proteasome system, CRBN–IKZF axis, glucocorticoid signaling, and immune effector pathways (NK/complement).